Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;35(11):e15800.
doi: 10.1111/dth.15800. Epub 2022 Sep 14.

Complete response of locally advanced cutaneous squamous cell carcinoma of the eyelid to topical imiquimod 3.75

Francesco Toso  1   2 , M Chiara Tronconi  3 , Andrea Cortese  1   2 , Giovanni Fiorillo  1   2 , Alessandra Bressan  4 , Antonio Costanzo  1   2 , Riccardo G Borroni  1   2
Affiliations

Complete response of locally advanced cutaneous squamous cell carcinoma of the eyelid to topical imiquimod 3.75

Francesco Toso et al. Dermatol Ther. 2022 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Erythematous, scaly, and well‐demarcated plaque located on the lower eyelid, extending up to the medial corner of the eye. (B) Histopathology of the lesion: squamous cell carcinoma, extensive intraepithelial component with solid token into the dermis (hematoxylin and eosin stain, ×5 magnification). (C) Clinical aspect of the lesion after 1 month of imiquimod 3.75% cream application: marked reduction in lesional size with crusts (crusting is an expected effect of topical imiquimod. (D) Clinical aspect of the lesion after 6 months of imiquimod 3.75% cream application: clear clinical improvement of the disease, without macroscopical signs of residual neoplasia
See this image and copyright information in PMC

References

    1. Garland SM. Imiquimod. Curr Opin Infect Dis. 2003;16(2):85‐89. doi:10.1097/00001432-200304000-00004 - DOI - PubMed
    1. Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(1):65‐69. doi:10.2174/187221312798889301 - DOI - PubMed
    1. Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. Epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60‐82. doi:10.1016/j.ejca.2020.01.007 - DOI - PubMed
    1. Avallone G, Merli M, Dell'Aquila C, et al. Imiquimod‐side effects in the treatment of periocular skin cancers: a review of the literature. Dermatol Ther. 2022;35(4):e15326. doi:10.1111/dth.15326 - DOI - PubMed
    1. Robustelli Test E, Fumo G, Corbeddu M, Ferreli C, Rongioletti F. Efficacy of Imiquimod 3.75% for the treatment of extensive Bowen's disease of the face in an elderly patient. Dermatol Ther. 2020;33(2):e13263. doi:10.1111/dth.13263 - DOI - PubMed

MeSH terms